Short Interest in Gossamer Bio Inc (NASDAQ:GOSS) Grows By 54.3%

Gossamer Bio Inc (NASDAQ:GOSS) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 5,030,000 shares, an increase of 54.3% from the August 30th total of 3,260,000 shares. Currently, 11.8% of the company’s shares are short sold. Based on an average daily trading volume, of 447,800 shares, the days-to-cover ratio is currently 11.2 days.

In other Gossamer Bio news, Director Faheem Hasnain purchased 10,000 shares of the stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $16.80 per share, for a total transaction of $168,000.00. Also, insider Luisa Salter-Cid sold 50,000 shares of Gossamer Bio stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $19.88, for a total transaction of $994,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have bought 40,821 shares of company stock valued at $275,497 and have sold 450,000 shares valued at $9,668,719. 23.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of GOSS. Omega Fund Management LLC acquired a new position in Gossamer Bio during the first quarter worth $150,681,000. FMR LLC acquired a new position in Gossamer Bio during the first quarter worth $26,576,000. Jennison Associates LLC acquired a new position in Gossamer Bio during the second quarter worth $14,630,000. BlackRock Inc. increased its holdings in Gossamer Bio by 63.1% during the second quarter. BlackRock Inc. now owns 1,295,224 shares of the company’s stock worth $28,729,000 after buying an additional 500,944 shares during the last quarter. Finally, Marshall Wace North America L.P. acquired a new position in Gossamer Bio during the first quarter worth $9,523,000. Institutional investors and hedge funds own 54.64% of the company’s stock.



Several research firms recently weighed in on GOSS. ValuEngine raised shares of Gossamer Bio from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, August 20th. Finally, Evercore ISI set a $30.00 price objective on shares of Gossamer Bio and gave the stock a “buy” rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $28.00.

Shares of GOSS stock traded down $0.26 during trading on Friday, reaching $14.83. The company’s stock had a trading volume of 395,792 shares, compared to its average volume of 830,792. The business has a fifty day moving average price of $19.08 and a 200-day moving average price of $19.38. The company has a quick ratio of 17.80, a current ratio of 17.80 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.03 billion and a price-to-earnings ratio of -0.66. Gossamer Bio has a one year low of $14.69 and a one year high of $25.06.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.18). Research analysts anticipate that Gossamer Bio will post -2.93 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Recommended Story: Why is cost of goods sold important?

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.